Modality
Small Molecule
MOA
SOS1i
Target
C5
Pathway
mTOR
Breast Ca
Development Pipeline
Preclinical
~Oct 2012
→ ~Jan 2014
Phase 1
~Apr 2014
→ ~Jul 2015
Phase 2
~Oct 2015
→ ~Jan 2017
Phase 3
~Apr 2017
→ ~Jul 2018
NDA/BLA
~Oct 2018
→ ~Jan 2020
Approved
Apr 2020
→ Jul 2025
ApprovedCurrent
NCT04738857
1,220 pts·Breast Ca
2020-04→2025-07·Recruiting
1,220 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2025-07-228mo agoPh3 Readout· Breast Ca
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
Approved
Recruit…
Catalysts
Ph3 Readout
2025-07-22 · 8mo ago
Breast Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04738857 | Approved | Breast Ca | Recruiting | 1220 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF |